Discover
AVIR
Atea Pharmaceuticals, Inc.
4.78
2 x 3.43
2 x 5.70
bid
ask
+
0.13
2.80%
2 @ 04:00 PM
4.78 +0.00 (0.00%)
| Ytd | 33.89% | |
| 1y | 32.78% |
4.63
day range
4.78
2.78
52 week range
6.45
| Open | 4.68 | Prev Close | 4.65 | Low | 4.63 | High | 4.78 | Mkt Cap | 382.53M |
| Vol | 472.56K | Avg Vol | 330.75K | EPS | -2.11 | P/E | N/A | Forward P/E | -2.12 |
| Beta | 0.17 | Short Ratio | 14.25 | Inst. Own | 71.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.76 | 200-d Avg | 4.16 | 1yr Est | 7.40 |
AVIR News
benzinga.com
Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America,
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026More Than 880 HCV Treatment-Naïv
globenewswire.com
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvi
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naï